Advertisement

Topics

Astellas Release:First Patient Dosed In Phase III MORPHO Trial Evaluating Gilteritinib As Maintenance Therapy Following Hematopoietic Stem Cell Transplant In Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia

20:00 EDT 21 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Astellas Release:First Patient Dosed In Phase III MORPHO Trial Evaluating Gilteritinib As Maintenance Therapy Following Hematopoietic Stem Cell Transplant In Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia

NEXT ARTICLE

More From BioPortfolio on "Astellas Release:First Patient Dosed In Phase III MORPHO Trial Evaluating Gilteritinib As Maintenance Therapy Following Hematopoietic Stem Cell Transplant In Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement